September 30, 2016 3:10 PM ET

Life Sciences Tools and Services

Company Overview of Yeda Research & Development Co. Ltd

Company Overview

Yeda Research & Development Co. Ltd., a technology transfer company, markets and commercializes the intellectual property developed by the scientists in the Weizmann Institute of Science. The company identifies and assesses research projects with commercial potential; protects the intellectual property of the institute and its scientists; creates business relationships and licenses the institute’s inventions and technologies to the industry; and channels funding from industry to research projects. Its portfolio covers a range of natural sciences, including biotechnology, pharmaceuticals, and diagnostics; bioinformatics, proteomics, biomatics, and system biology; medical devices; renewable en...

Weizman Institue of Science

Gilbert de Botton Building (Building No. 5)

P.O. Box 95

Rehovot,  76100

Israel

Founded in 1959

Phone:

972 8 947 0617

Fax:

972 8 947 0739

Key Executives for Yeda Research & Development Co. Ltd

Chief Executive Officer
Chief Financial Officer
Chief Intellectual Property Officer
General Counsel
Comptroller
Compensation as of Fiscal Year 2016.

Yeda Research & Development Co. Ltd Key Developments

Galmed Pharmaceuticals and Weizmann Institute Collaborate to Research Impact of Aramchol on Gut Microbiome

Galmed Pharmaceuticals signed an agreement with Yeda Research and Development. The pact is intended to assess the effects of the company's proprietary molecule, Aramchol, on the human gut microbiome. Under the terms, the company has a right to enter into exclusive negotiations with Yeda to complete a license deal to commercialize a diagnostic and/or prognostic tool for Aramchol and/or a diagnostic and/or prognostic tool in the field of liver disease.

TxCell SA Enters Agreement with Yeda Research and Development Co

TxCell SA reported the grant by the European Patent Office of the patent covering all redirected, genetically engineered T regulatory cells (CAR-Tregs) and their use in the suppression of autoimmune and inflammatory diseases. As a result, TxCell has exercised its option and signed an exclusive worldwide licensing agreement with Yeda Research and Development Co. Ltd. TxCell originally signed the option agreement with Yeda Research and Development Co. Ltd. in June 2015. As per the terms of the current license agreement, TxCell said that it has now been granted exclusive rights to, notably, develop and commercialize CAR-Treg products for the treatment of autoimmune and inflammatory diseases, as covered by the patent family. The company noted that the CAR-Treg patent family covered under its licensing agreement with Yeda originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar, who pioneered the CAR (Chimeric Antigen Receptor) approach. Professor Eshhar was the first scientist to demonstrate the therapeutic potential of CAR-Treg cells in preclinical models of intestinal inflammation. TxCell recently appointed Professor Eshhar as the Chairman of its newly established Scientific Advisory Board (SAB).

Stockton Israel and Yeda Research and Development Company Ltd. Sign an Extension to its Joint Research Agreement

Stockton Israel signed an extension to its joint research agreement with Yeda Research and Development Company Ltd., for the joint research with Prof. Assaf Aharoni'sPlant Sciences laboratory. The agreement includes an option for an exclusive, royalty bearing license to develop new Bioinsecticide. Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science, Rehovot, Israel. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education.

Similar Private Companies By Industry

Company Name Region
Alfa Rhythm Ltd. Middle East/Africa
AllergyFight Ltd. Middle East/Africa
Arcuro Medical Ltd. Middle East/Africa
Axonix Ltd. Middle East/Africa
Clal Life Sciences L.P. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Yeda Research & Development Co. Ltd, please visit www.yedarnd.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.